Dana-Farber Cancer Institute

bit.lyJoy in Medicine®: Recognized organizationsFind the recognition years, levels and locations for all currently recognized organizations in the Joy in Medicine® Health System Recognition Program.

We’re proud to be a recipient of the 2026 Joy in Medicine Health System Recognition Program from @ama-assn.org. View the list below.

Joyce Liu, MD, MPH, takes the stage at the Presidential Symposium III as a discussant on results from the phase 3 TroFuse-005/ENGOT-en23/GOG-3095 study, evaluating sacituzumab tirumotecan in patients with previously treated advanced or recurrent endometrial cancer. #ESMO26

Ravindra Uppaluri, MD, PhD, explores how surgical strategies may evolve following neoadjuvant immunotherapy, examining what these advances could mean for surgical decision-making and patient care. #ESMO26

The fourth day of poster presentations at #ESMO26 featured research on lung cancer, head and neck cancer, and thoracic malignancies.

Paolo Tarantino, MD, PhD, presents research using paired-biopsy multi-omic analysis to uncover target-independent mechanisms of antibody–drug conjugate (ADC) resistance in metastatic breast cancer. #ESMO26

Himisha Beltran, MD, kicks off the day during a "Challenge Your Expert" session focused on the challenges of managing neuroendocrine and small cell prostate cancer. #ESMO26

New findings from the phase 3 COSMIC-313 trial, presented by Wenxin (Vincent) Xu, MD, support the potential of KIM-1 to identify patients with advanced clear cell renal cell carcinoma who may benefit from immunotherapy alone versus immunotherapy plus cabozantinib.

These findings advance efforts to use biomarkers to guide more personalized treatment strategies for kidney cancer. #ESMO26

@drchoueiri.bsky.social presents the final protocol-prespecified analysis of the phase 3 KEYNOTE-564 trial, evaluating adjuvant pembrolizumab versus placebo in patients with clear cell renal cell carcinoma (ccRCC). #ESMO26

Elizabeth Mittendorf, MD, PhD, @ascopres, shares her perspective on leading teams in an increasingly complex oncology landscape during the ESMO-ASCO special session, “The Evolving Definition of the Modern Oncologist. #ESMO26

Nancy Lin,MD joins as an invited discussant for two studies exploring treatment approaches for CNS tumors. #ESMO26

@stolaney1.bsky.social, MD, MPH, presents on optimizing systemic therapy and treatment sequencing for patients with stage I HER2-positive early breast cancer during a session focused on advancing treatment approaches for HER2-positive disease.

Patrick Ott, MD, PhD, explores the evolving science of personalized cancer vaccines during the “All About Cancer Vaccines” educational session. #ESMO26

The phase 3 LITESPARK-012 trial, presented by @drchoueiri.bsky.social, show that adding either the HIF-2α inhibitor belzutifan or the CTLA-4 inhibitor quavonlimab to pembrolizumab and lenvatinib didn’t improve efficacy in previously untreated advanced clear cell renal cell carcinoma. #ESMO26

We’re back today at #ESMO26. Follow along here and with @danafarbernews as we learn and explore the latest in oncology care and research or join us at our upcoming discussions and poster presentations: bit.ly/4snmvAX

Jacob Sands MD, takes the stage at the Presidential Symposium to present findings from the phase 3 DeLLphi-305 trial. #ESMO26

bit.lyImmunotherapy combo extends survival for patients with aggressive small cell lung cancer, based on trial results presented by Dana-Farber at ESMO Congress 2026 | Dana-Farber Cancer InstituteIn patients with extensive-stage small cell lung cancer (ES-SCLC), tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more t...

This trial evaluates tarlatamab plus durvalumab versus durvalumab alone as first-line maintenance therapy for extensive-stage small cell lung cancer following initial treatment with durvalumab, platinum and etoposide. Learn more: bit.ly/4yz9ntL

Mary-Ellen Taplin, MD, is the senior author of research evaluating perioperative apalutamide plus androgen deprivation therapy alongside radical prostatectomy and pelvic lymph node dissection, compared with surgery alone, in patients with high-risk localized or locally advanced prostate cancer.

bit.lyPerioperative apalutamide in high-risk localized or locally advanced prostate cancer substudy supports reduced risk of metastasis and death | Dana-Farber Cancer InstituteAn international phase 3 clinical trial that treated patients with high-risk localized and locally advanced prostate cancer with apalutamide — a next-generation neoadjuvant androgen-receptor pathway i...

Learn more: bit.ly/47WyuvX #ESMO26

Findings from the phase 3 evERA Breast Cancer trial suggest giredestrant plus everolimus extended progression-free survival in patients with ER+/HER2– advanced breast cancer previously treated with CDK4/6 inhibitors.

@stolaney1 MD, MPH, shares these findings, supporting the combination’s potential across a broad range of patients. #ESMO26

Pasi A. Jänne, MD, PhD, chairs a discussion on breast and lung cancers, including atirmociclib plus fulvestrant for HR+/HER2– advanced breast cancer following CDK4/6 inhibitor progression and patient-reported outcomes with first-line trastuzumab deruxtecan in HER2-mutant NSCLC. #ESMO26

New findings from the phase 2 FOURLIGHT-1 study show that atirmociclib plus endocrine therapy improved median progression-free survival to 9.4 months, compared with 6.6 months with standard of care, in patients with HR+/HER2– metastatic breast cancer previously treated with CDK4/6 inhibitors.

Antonio Giordano, MD, PhD, shares atirmociclib’s potential as a next-generation, selective CDK4 inhibitor and supports its continued investigation as a treatment option for these patients. #ESMO26

#ESMO26 continues today! Follow along here and with @danafarbernews.bsky.social as we learn and explore the latest in oncology care and research, or join us at our upcoming discussions and poster presentations: bit.ly/4snmvAX

We’re pleased to share that Eliezer Van Allen, MD, of @vanallenlab.bsky.social has been named our inaugural Chief Artificial Intelligence (AI) Officer (CAIO). Please join us in congratulating him on this new role.

What’s next for immunotherapy in neuro-oncology? Lakshmi Nayak, MD, chairs the “Challenge Your Expert” special session, exploring what’s on the horizon for immune-modulating approaches in neuro-oncology. #ESMO26

The first day of poster presentations at #ESMO26 featured new research from metastatic prostate, renal, and urothelial cancers.

@drchoueiri.bsky.social shares his perspective on mRNA vaccines during a special session exploring what oncologists should know about this evolving approach to cancer treatment. #ESMO26

"The word I'd use to describe mRNA vaccines is: flexible." - @drchoueiri.bsky.social

Patrick Ott, MD, PhD, presents emerging approaches using peptides, DNA, mRNA and more at the Special Symposium on Melanoma: From Standard Fit to Bespoke Care. #ESMO26

We’re excited to be at #ESMO26! Follow along here and with @danafarbernews.bsky.social as we learn and explore the latest in oncology care and research, or join us at our upcoming discussions and poster presentations: bit.ly/4snmvAX

From the Presidential Symposium to key disease-focused sessions, our researchers are bringing impactful new data to #ESMO26. This week’s presentations span lung, prostate, breast, and kidney cancer, along with special sessions on personalized cancer vaccines. See what’s ahead: bit.ly/4zJ87oL

bit.lyDana-Farber, Beth Israel to begin construction of new $1.68 billion cancer hospital - The Boston GlobeThe groundbreaking marks a new phase in the competition with Mass General Brigham. About 2,400 workers will be hired at the facility over the next four years.

Yesterday’s groundbreaking for the Lavine Bekenstein Hospital at Dana-Farber marks an important step toward the future of cancer care for patients, families, clinicians, and researchers across our region and beyond. Learn more in the @bostonglobe.com.

Join our Direct Connect program for an upcoming webinar featuring Elizabeth O’Donnell, MD. O’Donnell will discuss innovative approaches to detecting and intercepting cancer early, including multi-cancer blood tests and prevention strategies. Learn more and register here: bit.ly/4dmuIz4

Congratulations to Zuzana Tothova, MD, PhD, recipient of our Postdoctoral and Graduate Student Association's Mentor-of-the-Year Award. Dr. Tothova empowers trainees through thoughtful guidance, unwavering support, and a collaborative lab culture that helps young scientists grow with confidence.

Brian Wolpin, MD, MPH, and Jia Luo, MD, took the stage at the @statnews.com STAT Summit for "New Weapons Against Cancer", a conversation about KRAS, the year’s biggest advances in targeted therapy, and the momentum shaping the future of oncology.

bit.lyDana-Farber’s Rachel Pozzar, PhD, APRN, FAAN, inducted into American Academy of Nursing 2026 Class of Fellows | Dana-Farber Cancer InstituteRachel Pozzar, PhD, APRN, FAAN, a nurse scientist in the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services at Dana-Farber Cancer Institute, has been inducted into the American Academy of Nursing 2026 Class of Fellows.

Rachel Pozzar, PhD, APRN, FAAN, a nurse scientist in the Phyllis F. Cantor Center for Research in Nursing and Patient Care Services, has been inducted into the American Academy of Nursing 2026 Class of Fellows. Please join us in congratulating her on this honor.

bit.lyNovel Treatment Combination Improves Progression-Free Survival in Most Common Form of Metastatic Breast CancerPatients with estrogen-receptor-positive (ER+) HER-2-negative advanced breast cancer experienced significantly improved progression-free survival (PFS) when treated with an oral combination regimen that included giredestrant, a novel, next-generation selective ER degrader and full antagonist (SERD), compared to a standard combination approach.

Patients with estrogen-receptor-positive (ER+) HER-2-negative advanced breast cancer experienced significantly improved progression-free survival when treated with an oral combination regimen, compared to a standard combination approach.

bit.lyBuilding a System of Focused Care for Lobular Breast CancerDana-Farber investigators are pioneering new approaches to help understand, diagnose, and treat this distinct form of breast cancer.

Lobular breast cancer has distinct biological and clinical features that warrant a more tailored approach. Learn how our investigators are working to better understand, diagnose, and treat it.

Dana-Farber Cancer Institute reposted

This week @danafarber.bsky.social welcomed two distinguished leaders: Seth Karp, MD, began his new role as Chair of Surgery, and Gavin P. Dunn, MD, PhD, is now Neurosurgeon-in-Chief at the institute. Read more: bit.ly/4AUc37P

Dana-Farber Cancer Institute reposted

bit.lyCancer Vaccines Are the N.I.H’s Next ‘Big Bet’New details have emerged about an initiative that starts in December to fast-track the vaccines, similar to the successful push for the Covid-19 vaccine.

Cancer vaccines featured in @nytimes.com: Following encouraging melanoma and kidney cancer studies led by @danafarber.bsky.social, Dr. Cathy Wu and colleagues are now developing vaccines for patients with glioblastoma and ovarian cancer. ➡️bit.ly/3UhpL40

Dana-Farber Cancer Institute reposted

Congratulations to @danafarber.bsky.social’s Mary-Ellen Taplin, MD, who was honored with the Prostate Cancer Foundation's Women in Science Lifetime Achievement Award. Read more: bit.ly/4zj9nPh

Dana-Farber Cancer Institute reposted

Congratulations to @danafarber.bsky.social’s @nickpolizzi.bsky.social and Xin Gu, PhD, recipients of NIH New Innovator Awards supporting early career investigators pursuing highly innovative research with potential for broad impact on biomedical and behavioral science. ➡️bit.ly/4hKLs46

bit.lyNew Cancer Drugs Are Revolutionary. Why Don’t More Patients Get Them?Targeted gene therapies are highly effective at stopping cancers, but the very abundance of the treatments, plus cost and sluggish change, are hindering access.

“If you go back 20 years, metastatic lung cancer was a death sentence,” said Matthew Meyerson, MD, PhD, a lung cancer researcher and Charles A. Dana Chair in Human Cancer Genetics (II). “Now there are huge numbers of patients surviving five years, 10 years, 20 years.” Read more in the @nytimes.com ⬇

bit.ly100 hospitals and health systems with great oncology programs | 2026 - Becker's OncologyCancer care is one of medicine’s greatest frontiers, and the institutions on this list are leading the charge. Becker’s is proud to unveil its 2026 list of hospitals and health systems recognized for excellence in oncology. This list celebrates the cancer programs that are setting the standard for what exceptional, innovative, patient-centered cancer care looks […]

We're proud to be included in Becker's 100 hospitals and health systems with great oncology programs 2026 list. Learn more and view the full list below.

Congratulations to @sidujain.bsky.social, a postdoctoral fellow in the Kadoch Lab, on receiving an NCI K99/R00 Pathway-to-Independence Award for his exceptional research and plans for his independent laboratory. Explore more of his work here: bit.ly/4iv3f1m

Dana-Farber Cancer Institute reposted

In today’s @nejm.org, @danafarber.bsky.social’s @elmayermd.bsky.social is publishing results of the evERA study showing a novel combination can substantially improve disease control in patients with ER+ metastatic breast cancer compared to standard of care. ➡️bit.ly/4yoG8KS